Post-kala-azar dermal leishmaniasis

Last updated
PKDL lesions on hand. Leshmaniasis new photo to help in diagnosis.jpg
PKDL lesions on hand.

Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL); it is characterised by a macular, maculopapular, and nodular rash in a patient who has recovered from VL and who is otherwise well. The rash usually starts around the mouth from where it spreads to other parts of the body depending on severity.

Contents

Post-kala-azar dermal leishmaniasis (also known as "Post-kala-azar dermatosis") found mainly on the face, arms, and upper part of the trunk. It occurs years (in the Indian variation) or a few months (in the African strain) after the successful treatment of visceral leishmaniasis.

It is mainly seen in Sudan and India where it follows treated VL in 50% and 5–10% of cases, respectively. Thus, it is largely restricted to areas where Leishmania donovani is the causative parasite. The interval at which PKDL follows VL is 0–6 months in Sudan and 2–3 years in India. PKDL probably has an important role in interepidemic periods of VL, acting as a reservoir for parasites.

PKDL was first identified by Sir Upendranath Brahmachari, who initially called it dermal leishmanoid. He published his observations in the Indian Medical Gazette in 1922. [1]

Mechanism

The cause of PKDL is uncertain. [2] Possibilities may include use of antimonial drugs, sunburn, reinfection with kala-azar, memory T cell responses failing in certain organs; and genetic susceptibility. [2]

There is increasing evidence that the pathogenesis is largely immunologically mediated; high concentrations of interleukin 10 in the peripheral blood of VL patients predict the development of PKDL. During VL, interferon gamma is not produced by peripheral blood mononuclear cells (PBMC). After treatment of VL, PBMCs start producing interferon gamma, which coincides with the appearance of PKDL lesions due to interferon-gamma-producing cells causing skin inflammation as a reaction to persisting parasites in the skin.[ citation needed ]

Diagnosis

PKDL is difficult to diagnose. [3]

Diagnosis is mainly clinical, but parasites can be seen by microscopy in smears with limited sensitivity. [3] PCR and monoclonal antibodies may detect parasites in more than 80% of cases. Serological tests and the leishmanin skin test are of limited value.[ citation needed ]

Treatment

Treatment is always needed in Indian PKDL; in Sudan, most cases are self-limited but severe and chronic cases are treated. Sodium stibogluconate is given at 20 mg/kg for 2 months in Sudan and for 4 months in India. Liposomal amphotericine B seems effective. Although research has brought many new insights in pathogenesis and management of PKDL, several issues in particular in relation to control remain unsolved and deserve urgent attention.[ citation needed ]

Miltefosine is the only available oral medication available for VL and PKDL. [4] While the drug works for short-term treatment of VL, PKDL would require a longer treatment of more than 28 days with this drug. [4] Miltefosine is not recommended for use as a monotherapy to treat PKDL. [4]

The risk of human immunodeficiency virus (HIV) co-infection in patients with visceral leishmaniasis (VL) or kala-azar in endemic areas has posed a major challenge in control. [5]

Society and culture

People with PKDL are a reservoir of leishmaniasis. [6] To eliminate leishmaniasis from a population, people with PKDL must get treatment. [6]

The government of India has an kala-azar elimination program ongoing which entered a consolidation phase in 2017. [7]

See also

Related Research Articles

<i>Leishmania</i> Genus of parasitic flagellate protist

Leishmania is a parasitic protozoan, a single-celled organism of the genus Leishmania that is responsible for the disease leishmaniasis. They are spread by sandflies of the genus Phlebotomus in the Old World, and of the genus Lutzomyia in the New World. At least 93 sandfly species are proven or probable vectors worldwide. Their primary hosts are vertebrates; Leishmania commonly infects hyraxes, canids, rodents, and humans.

<span class="mw-page-title-main">Leishmaniasis</span> Disease caused by parasites of the Leishmania type

Leishmaniasis is a wide array of clinical manifestations caused by protozoal parasites of the Trypanosomatida genus Leishmania. It is generally spread through the bite of phlebotomine sandflies, Phlebotomus and Lutzomyia, and occurs most frequently in the tropics and sub-tropics of Africa, Asia, the Americas, and southern Europe. The disease can present in three main ways: cutaneous, mucocutaneous, or visceral. The cutaneous form presents with skin ulcers, while the mucocutaneous form presents with ulcers of the skin, mouth, and nose. The visceral form starts with skin ulcers and later presents with fever, low red blood cell count, and enlarged spleen and liver.

<span class="mw-page-title-main">William Boog Leishman</span> British Army general

Lieutenant-General Sir William Boog Leishman, was a Scottish pathologist and British Army medical officer. He was Director-General of Army Medical Services from 1923 to 1926.

<i>Phlebotomus</i> Genus of flies

Phlebotomus is a genus of "sand flies" in the Diptera family Psychodidae. In the past, they have sometimes been considered to belong in a separate family, Phlebotomidae, but this alternative classification has not gained wide acceptance.

<span class="mw-page-title-main">Cutaneous leishmaniasis</span> Medical condition

Cutaneous leishmaniasis is the most common form of leishmaniasis affecting humans. It is a skin infection caused by a single-celled parasite that is transmitted by the bite of a phlebotomine sand fly. There are about thirty species of Leishmania that may cause cutaneous leishmaniasis.

<span class="mw-page-title-main">Visceral leishmaniasis</span> Human disease caused by protist parasites

Visceral leishmaniasis (VL), also known as kala-azar or "black fever", is the most severe form of leishmaniasis and, without proper diagnosis and treatment, is associated with high fatality. Leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania.

<span class="mw-page-title-main">Upendranath Brahmachari</span> Indian physician (1873–1946)

Rai Bahadur Sir Upendranath Brahmachari was a prominent Indian physician and scientist. In 1922, he synthesised urea-stibamine (carbostibamide) and demonstrated its effectiveness in treating kala-azar.

Pentavalent antimonials are a group of compounds used for the treatment of leishmaniasis. They are also called pentavalent antimony compounds.

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

<span class="mw-page-title-main">Miltefosine</span> Phospholipid drug

Miltefosine, sold under the trade name Impavido among others, is a medication mainly used to treat leishmaniasis and free-living amoeba infections such as Naegleria fowleri and Balamuthia mandrillaris. This includes the three forms of leishmaniasis: cutaneous, visceral and mucosal. It may be used with liposomal amphotericin B or paromomycin. It is taken by mouth.

Antiparasitics are a class of medications which are indicated for the treatment of parasitic diseases, such as those caused by helminths, amoeba, ectoparasites, parasitic fungi, and protozoa, among others. Antiparasitics target the parasitic agents of the infections by destroying them or inhibiting their growth; they are usually effective against a limited number of parasites within a particular class. Antiparasitics are one of the antimicrobial drugs which include antibiotics that target bacteria, and antifungals that target fungi. They may be administered orally, intravenously or topically. Overuse or misuse of antiparasitics can lead to the development of antimicrobial resistance.

<span class="mw-page-title-main">Canine leishmaniasis</span> Disease affecting dogs

Canine leishmaniasis (LEESH-ma-NIGH-ah-sis) is a zoonotic disease caused by Leishmania parasites transmitted by the bite of an infected phlebotomine sandfly. There have been no documented cases of leishmaniasis transmission from dogs to humans. Canine leishmaniasis was first identified in Europe in 1903, and in 1940, 40% of all dogs in Rome were determined to be positive for leishmaniasis. Traditionally thought of as a disease only found near the Mediterranean basin, 2008 research claims new findings are evidence that canine leishmaniasis is currently expanding in continental climate areas of northwestern Italy, far from the recognized disease-endemic areas along the Mediterranean coasts. Cases of leishmaniasis began appearing in North America in 2000, and, as of 2008, Leishmania-positive foxhounds have been reported in 22 U.S. states and two Canadian provinces.

<i>Leishmania donovani</i> Species of intracellular parasite

Leishmania donovani is a species of intracellular parasites belonging to the genus Leishmania, a group of haemoflagellate kinetoplastids that cause the disease leishmaniasis. It is a human blood parasite responsible for visceral leishmaniasis or kala-azar, the most severe form of leishmaniasis. It infects the mononuclear phagocyte system including spleen, liver and bone marrow. Infection is transmitted by species of sandfly belonging to the genus Phlebotomus in Old World and Lutzomyia in New World. The species complex it represents is prevalent throughout tropical and temperate regions including Africa, China, India, Nepal, southern Europe, Russia and South America. The species complex is responsible for thousands of deaths every year and has spread to 88 countries, with 350 million people at constant risk of infection and 0.5 million new cases in a year.

<i>Leishmania tropica</i> Species of protozoan parasite

Leishmania tropica is a flagellate parasite and the cause of anthroponotic cutaneous leishmaniasis in humans. This parasite is restricted to Afro-Eurasia and is a common cause of infection in Afghanistan, Iran, Syria, Yemen, Algeria, Morocco, and northern India.

Leishmania braziliensis is a Leishmania species found in South America. It is associated with leishmaniasis.

Neglected tropical diseases in India are a group of bacterial, parasitic, viral, and fungal infections that are common in low income countries but receive little funding to address them. Neglected tropical diseases are common in India.

Kala azar in India refers to the special circumstances of the disease kala azar as it exists in India. Kala azar is a major health problem in India with an estimated 146,700 new cases per year as of 2012. In the disease a parasite causes sickness after migrating to internal organs such as the liver, spleen and bone marrow. If left untreated the disease almost always results in the death. Signs and symptoms include fever, weight loss, fatigue, anemia, and substantial swelling of the liver and spleen.

<span class="mw-page-title-main">Leishmaniasis vaccine</span> Vaccine against leishmaniasis

A Leishmaniasis vaccine is a vaccine which would prevent leishmaniasis. As of 2017, no vaccine for humans was available. Currently some effective leishmaniasis vaccines for dogs exist.

Shyam Sundar is an Indian academic and professor at Banaras Hindu University. He works on Infectious Diseases - Leishmaniasis & HIV/AIDS.

<span class="mw-page-title-main">Ahmed Mohamed El Hassan</span> Sudanese medical scientist (1930–2022)

Ahmed Mohamed El HassanFRCP FTWAS was a Sudanese professor of pathology.

References

  1. Brahmachari, U. N. (April 1922). "A New Form of Cutaneous Leishmaniasis—Dermal Leishmanoid". The Indian Medical Gazette. 57 (4): 125–127. ISSN   0019-5863. PMC   5186533 . PMID   29008368.
  2. 1 2 Mukhopadhyay, D; Dalton, JE; Kaye, PM; Chatterjee, M (February 2014). "Post kala-azar dermal leishmaniasis: an unresolved mystery". Trends in Parasitology. 30 (2): 65–74. doi:10.1016/j.pt.2013.12.004. PMC   3919212 . PMID   24388776.
  3. 1 2 Zijlstra, EE (2019). "Biomarkers in Post-kala-azar Dermal Leishmaniasis". Frontiers in Cellular and Infection Microbiology. 9: 228. doi: 10.3389/fcimb.2019.00228 . PMC   6685405 . PMID   31417876.
  4. 1 2 3 Pijpers, J; den Boer, ML; Essink, DR; Ritmeijer, K (February 2019). "The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis". PLOS Neglected Tropical Diseases. 13 (2): e0007173. doi: 10.1371/journal.pntd.0007173 . PMC   6386412 . PMID   30742620.
  5. PK Sinha, Sanjiva Bimal, SK Singh, Krishna Pandey, DN Gangopadhyay, SK Bhattacharya (1 March 2006). "Pre- & post-treatment evaluation of immunological features in Indian visceral leishmaniasis (VL) patients with HIV co-infection".{{cite web}}: CS1 maint: multiple names: authors list (link)
  6. 1 2 Ganguly, S; Das, NK; Barbhuiya, JN; Chatterjee, M (August 2010). "Post-kala-azar dermal leishmaniasis—an overview". International Journal of Dermatology. 49 (8): 921–31. doi:10.1111/j.1365-4632.2010.04558.x. PMID   21128917. S2CID   23294429.
  7. Zijlstra, EE; Alves, F; Rijal, S; Arana, B; Alvar, J (November 2017). "Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme". PLOS Neglected Tropical Diseases. 11 (11): e0005877. doi: 10.1371/journal.pntd.0005877 . PMC   5689828 . PMID   29145397.